Enzo Biochem Stock News

NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced its 2021 Annual Meet

NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced two key appointments

Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q2 2022 Results - Earnings Call Transcript

Enzo Biochem press release (NYSE:ENZ): FQ2 Non-GAAP EPS of $0.03.Revenue of $34.05M (+8.2% Y/Y).Shares +11.3%.

Conference call and live webcast scheduled for today,Monday, March 14, 2022 at 4:30 pm (ET)

NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Ma

NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets'' Life Sciences & MedTech Investor Forum , Tuesday, March 22, 2022 at 3:00pm Eastern Time. The format will be a "fireside chat" discussion hosted by KeyBanc''s Research Analyst Paul Knight. Hamid Erfanian, Chief Executive Officer and David Bench, Chief Financial Officer, will be scheduling virtual 1x1 meetings on March 22. If you are interested in arranging a one-on-one meeting, please contact your KeyBanc representative. A webcast of the presentation can be followed live via the following link: Webcast Presentation Link –Click Here or please visit the "Upcoming Events" section within the "Investor Information" page of the Enzo Biochem website at www.enzo.com About KeyBanc Capital Markets KeyBanc Capital Markets has more than $50 billion of capital committed to clients and an award-winning Equity Research team that provides coverage on …

NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Mark

Conference Call and Webcast Scheduled for March 14, 2022, 4:30 pm ET

Enzo Biochem (ENZ) announced that on Jan. 21 the company served a notice of termination to former CEO Elazar Rabbani regarding his employment

NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of

Genetron (NASDAQ:GTH) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Profitability This table compares Genetron and Enzo Biochems net margins, return on equity and return on []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug Calliditas Therapeutics AB (